Scott Goodman, a fellow prostate cancer survivor, has agreed to occasionally post on the blog. Scott, at the age of 45 years, was diagnosed with prostate cancer. In two short years, he has been diagnosed, undergone surgery, taken Ketoconazole with Prednisone and now finds himself starting chemotherapy. Scott bravely has agreed to chronicle his journey [...]
Today, Cougar Biotechnology, Inc. (NASDAQ:CGRB) unveiled the results from its ongoing Phase II clinical trial drug CB7630 (abiraterone acetate). The data was presented at the Prostate Cancer Foundation Scientific Retreat in Lake Tahoe, Nevada. The clinical trial, which is centered at the M.D. Anderson Cancer Center in Texas and was designed to look at the [...]
It is common knowledge that androgens play a role in the production of red blood cells. The lack of androgens cause the hematocrit (proportion of blood volume that is occupied by red blood cells) level to fall in most men with prostate cancer who are on a hormone blockade. About 10% of men on a [...]
There have been very few studies on the patterns of care and outcome of elderly (over 75 years) survivors with androgen independent prostate cancer (AIPC) who have been treated with docetaxel (Taxotere). The records of 175 French men with AIPC, over the age of 75 years, were retrospectively examined. All of the men were treated [...]
Once we develop metastatic androgen-independent prostate cancer and experience disease progression after receiving docetaxel-based chemotherapy we have no approved treatment options. We have hit the proverbial wall! In the process of attempting to develop additional treatments, ImClone Systems Inc. (NASDAQ: IMCL), announced the beginning of a Phase II clinical trial for men with advanced prostate [...]